ArticleInfectious diseases and therapy2024

Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan.

Chun-Chi Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.